The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit. The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of OS and PFS in advanced or metastatic UC. Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology. Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV. The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit. Anke Richters, PhD, discusses how not reporting primary end point changes in clinical trials can lead to issues. Perioperative durvalumab with gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years. Older patients over 70 years of age need improved care and management of UTUC to improve their outcomes. Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC. The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques. Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon. Dr. Prasad provides overviews of ATLAS and ENVISION and opines on whether UGN-102 is a practice-ready alternative to TURBT. Somatic alterations in DDR genes are common in patients with advanced urothelial cancer. Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC. Patients who had initiated AC 90 days after RNU were examined to determine a relation between treatment efficacy and timing. Several urologists weigh in on BCG, its role in NMIBC treatment, shortages, and strategies to treat BCG-unresponsive disease. Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC. Patients with cN+ m0 BCa had similar survival outcomes whether treated with surgery or radical therapy. Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab. Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab.